person · Reporting owner

Brege Laura

Disclosed activity across 7 companies

Tapewire entity: 37268
SEC CIK: 0001365619

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ACADIA PHARMACEUTICALS INCACAD · Entity 3913	Director	May 29, 2026	June 01, 2026
ARATANA THERAPEUTICS, INC.PETX · Entity 155913	Director	July 27, 2018	July 30, 2018
DYNAVAX TECHNOLOGIES CORPDVAX · Entity 66930	Director	May 30, 2019	May 31, 2019
Edgewise Therapeutics, Inc.EWTX · Entity 3965	Director	June 05, 2026	June 17, 2026
Mirum Pharmaceuticals, Inc.MIRM · Entity 2416	Director	June 15, 2026	June 18, 2026
Pacira BioSciences, Inc.PCRX · Entity 4928	Director	June 10, 2026	June 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACADIA PHARMACEUTICALS INC

Report date May 29, 2026 · Filed June 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	23,202	Reported balance After 2026-05-29 transaction · row 1 1 source row Row 1 · 2026-05-29 · Exercise / conversion · Acquired 8,107 · Balance 23,202 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-29 · Exercise / conversion · Disposed 8,107 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	9,311	Reported balance After 2026-05-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-29 · Grant · Acquired 9,311 · Balance 9,311 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.
Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.66 · Expires 2036-05-28	Direct	16,004	Reported balance After 2026-05-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-29 · Grant · Acquired 16,004 · Balance 16,004 F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.

F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.

F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.

ARATANA THERAPEUTICS, INC.

Report date July 27, 2018 · Filed July 30, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	13,500	Reported balance After 2018-07-27 transaction · row 1 1 source row Row 1 · 2018-07-27 · Grant · Acquired 4,500 · Balance 13,500
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2028-07-26	Direct	7,500	Reported balance After 2018-07-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-07-27 · Grant · Acquired 7,500 · Balance 7,500 F1: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date.

DYNAVAX TECHNOLOGIES CORP

Report date May 30, 2019 · Filed May 31, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.97 · Expires 2026-05-29	Direct	15,000	Reported balance After 2019-05-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-05-30 · Grant · Acquired 15,000 · Balance 15,000 F2: Not applicable. F1: This option vests fully on May 30, 2020, on the one year anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests fully on May 30, 2020, on the one year anniversary of the grant date.

F2: Not applicable.

Edgewise Therapeutics, Inc.

Report date June 05, 2026 · Filed June 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.59 · Expires 2036-06-05	Direct	16,377	Reported balance After 2026-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-05 · Grant · Acquired 16,377 · Balance 16,377 F1: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

Mirum Pharmaceuticals, Inc.

Report date June 15, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $101.00 · Expires 2036-06-14	Direct	3,772	Reported balance After 2026-06-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-15 · Grant · Acquired 3,772 · Balance 3,772 F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
Deferred Stock UnitsSEC Table II · derivative / convertible security	Direct	1,980	Reported balance After 2026-06-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-15 · Grant · Acquired 1,980 · Balance 1,980 F2: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.

F2: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.

Pacira BioSciences, Inc.

Report date June 10, 2026 · Filed June 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	30,120	Reported balance After 2026-06-10 transaction · row 1 1 source row Row 1 · 2026-06-10 · Grant · Acquired 6,405 · Balance 30,120 F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.42 · Expires 2036-06-10	Direct	10,891	Reported balance After 2026-06-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-10 · Grant · Acquired 10,891 · Balance 10,891 F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PORTOLA PHARMACEUTICALS INC

Report date July 02, 2020 · Filed July 02, 2020

Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-07-02 transaction · row 1 1 source row Row 1 · 2020-07-02 · Disposition to issuer · Disposed 13,194 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
Restricted Stock UnitsSEC Table I · non-derivative	Direct	Reported balance After 2020-07-02 transaction · row 2 1 source row Row 2 · 2020-07-02 · Disposition to issuer · Disposed 7,281 · Balance 0 F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2030-06-11	Direct	Reported balance After 2020-07-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-07-02 · Disposition to issuer · Disposed 11,377 · Balance 0 F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-07-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-07-02 · Disposition to issuer · Disposed 44,991 · Balance 0 F4: In connection with the Merger, these options were accelerated and canceled without payment.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.

F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F4: In connection with the Merger, these options were accelerated and canceled without payment.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 12, 2023 Filed Jan 17, 2023 22:17 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	12,500	$17.01	$212,625.00	Disclosure SEC source: 0001209191-23-003554 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 24, 2022 Filed Jun 28, 2022 23:16 UTC	Edgewise Therapeutics, Inc. EWTX · Entity 3965	GrantStock Option (Right to Buy) · Derivative	42,087	$0.00 Strike: $8.53	$0.00	Disclosure SEC source: 0001562180-22-005383 · primarydocument.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,087 Underlying: Common Stock · 42,087 shares Expires 2032-06-24 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 24, 2022 will become vested on the earlier of (i) June 24, 2023 or (ii) the business day prior to the date of the 2023 annual meeting of stockholders. Read SEC document
June 08, 2022 Filed Jun 8, 2022 23:18 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantStock Option (Right to Buy) · Derivative	8,225	$0.00 Strike: $59.39	$0.00	Disclosure SEC source: 0001209191-22-035215 · doc4.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,225 Underlying: Common Stock · 8,225 shares Expires 2032-06-08 Read SEC document
June 08, 2022 Filed Jun 8, 2022 23:18 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantCommon Stock	1,160	$0.00	$0.00	Disclosure SEC source: 0001209191-22-035215 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,147 F1 · shares: Represents restricted stock units that vest on June 3, 2023, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document
June 07, 2022 Filed Jun 10, 2022 00:17 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantRestricted Stock Units · Derivative	8,552	$0.00	$0.00	Disclosure SEC source: 0001209191-22-035662 · doc4.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,552 Underlying: Common Stock · 8,552 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F3 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document
June 07, 2022 Filed Jun 10, 2022 00:17 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantDirector Stock Options (Right to Buy) · Derivative	14,368	$0.00 Strike: $18.27	$0.00	Disclosure SEC source: 0001209191-22-035662 · doc4.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,368 Underlying: Common Stock · 14,368 shares Expires 2032-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document
June 07, 2022 Filed Jun 6, 2023 01:42 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	6,391	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034697 · doc4.xml · derivative · entry 5 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,391 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document
June 07, 2022 Filed Jun 6, 2023 01:42 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	6,391	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-034697 · doc4.xml · nonDerivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document
June 02, 2022 Filed Jun 6, 2022 22:07 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantStock Option (right to buy) · Derivative	17,000	$0.00 Strike: $23.51	$0.00	Disclosure SEC source: 0001209191-22-034648 · doc4.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2023 annual stockholder meeting. Read SEC document
June 22, 2021 Filed Jun 24, 2021 20:38 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantRestricted Stock Units · Derivative	6,391	$0.00	$0.00	Disclosure SEC source: 0001209191-21-043035 · doc4.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,391 Underlying: Common Stock · 6,391 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F3 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document
June 22, 2021 Filed Jun 24, 2021 20:38 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantDirector Stock Options (Right to Buy) · Derivative	11,637	$0.00 Strike: $24.88	$0.00	Disclosure SEC source: 0001209191-21-043035 · doc4.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,637 Underlying: Common Stock · 11,637 shares Expires 2031-06-21 F1 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document
June 22, 2021 Filed Jun 6, 2023 01:42 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	3,059	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034697 · doc4.xml · derivative · entry 4 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,059 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document
June 22, 2021 Filed Jun 6, 2023 01:42 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	3,059	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-034697 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document
June 09, 2021 Filed Jun 12, 2021 00:30 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantStock Option (Right to Buy) · Derivative	7,626	$0.00 Strike: $60.96	$0.00	Disclosure SEC source: 0001209191-21-040079 · doc4.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,626 Underlying: Common Stock · 7,626 shares Expires 2031-06-09 Read SEC document
June 09, 2021 Filed Jun 12, 2021 00:30 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantCommon Stock	1,066	$0.00	$0.00	Disclosure SEC source: 0001209191-21-040079 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,987 F1 · shares: Represents restricted stock units that vest on June 3, 2022, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document
June 04, 2021 Filed Jun 8, 2021 20:46 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantStock Option (right to buy) · Derivative	17,000	$0.00 Strike: $16.88	$0.00	Disclosure SEC source: 0001209191-21-038946 · doc4.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2022 annual stockholder meeting. Read SEC document
November 16, 2020 Filed Nov 17, 2020 22:39 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $13.98	$0.00	Disclosure SEC source: 0001209191-20-058830 · doc4.xml · derivative · entry 3 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2021-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable in 24 equal monthly installments beginning on July 2, 2011. Read SEC document
November 16, 2020 Filed Nov 17, 2020 22:39 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	SaleCommon Stock	12,000	$65.95	$791,400.00	Disclosure SEC source: 0001209191-20-058830 · doc4.xml · nonDerivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,921 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.930 to $66.015, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 16, 2020 Filed Nov 17, 2020 22:39 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionCommon Stock	12,000	$13.98	$167,760.00	Disclosure SEC source: 0001209191-20-058830 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:24 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerStock Option (Right to Buy) · Derivative	44,991	$0.00	$0.00	Disclosure SEC source: 0001209191-20-040301 · doc4.xml · derivative · entry 4 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,991 shares Expires not disclosed F4 · derivative.exercise_price: In connection with the Merger, these options were accelerated and canceled without payment. F4 · price: In connection with the Merger, these options were accelerated and canceled without payment. F4 · derivative.exercise_date: In connection with the Merger, these options were accelerated and canceled without payment. F4 · derivative.expiration_date: In connection with the Merger, these options were accelerated and canceled without payment. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:24 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerStock Option (Right to Buy) · Derivative	11,377	$0.06 Strike: $17.94	$682.62	Disclosure SEC source: 0001209191-20-040301 · doc4.xml · derivative · entry 3 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,377 shares Expires 2030-06-11 F3 · price: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. F3 · derivative.exercise_date: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:24 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerRestricted Stock Units	7,281	$18.00	$131,058.00	Disclosure SEC source: 0001209191-20-040301 · doc4.xml · nonDerivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · acquired: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:24 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerCommon Stock	13,194	$18.00	$237,492.00	Disclosure SEC source: 0001209191-20-040301 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. Read SEC document
June 23, 2020 Filed Jun 25, 2020 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantRestricted Stock Units · Derivative	3,059	$0.00	$0.00	Disclosure SEC source: 0001209191-20-038976 · doc4.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,059 Underlying: Common Stock · 3,059 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F3 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document
June 23, 2020 Filed Jun 25, 2020 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantDirector Stock Options (Right to Buy) · Derivative	5,579	$0.00 Strike: $52.73	$0.00	Disclosure SEC source: 0001209191-20-038976 · doc4.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,579 Underlying: Common Stock · 5,579 shares Expires 2030-06-22 F1 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document
June 12, 2020 Filed Jun 15, 2020 18:49 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantStock Option (Right to Buy) · Derivative	11,377	$0.00 Strike: $17.94	$0.00	Disclosure SEC source: 0001209191-20-036756 · doc4.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,377 Underlying: Common Stock · 11,377 shares Expires 2030-06-11 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document
June 12, 2020 Filed Jun 15, 2020 18:49 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	7,281	$0.00	$0.00	Disclosure SEC source: 0001209191-20-036756 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,475 F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs fully vest on March 1, 2021, subject to the Reporting Person's Continuous Services (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Read SEC document
June 11, 2020 Filed Jun 15, 2020 20:15 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantStock Option (right to buy) · Derivative	14,167	$0.00 Strike: $16.71	$0.00	Disclosure SEC source: 0001209191-20-036581 · doc4.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,167 Underlying: Common Stock · 14,167 shares Expires 2030-06-10 F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2021 annual stockholder meeting. Read SEC document
June 09, 2020 Filed Jun 11, 2020 22:21 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantStock Option (Right to Buy) · Derivative	8,027	$0.00 Strike: $47.65	$0.00	Disclosure SEC source: 0001209191-20-036033 · doc4.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,027 Underlying: Common Stock · 8,027 shares Expires 2030-06-09 Read SEC document
June 09, 2020 Filed Jun 11, 2020 22:21 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantCommon Stock	1,260	$0.00	$0.00	Disclosure SEC source: 0001209191-20-036033 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,921 F1 · shares: Represents restricted stock units that vest on June 3, 2021, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document
June 05, 2020 Filed Jun 9, 2020 01:04 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	SaleCommon Stock	2,100	$48.70	$102,270.00	Disclosure SEC source: 0001209191-20-035169 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,661 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document
January 07, 2020 Filed Jan 8, 2020 23:01 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $1.75	$0.00	Disclosure SEC source: 0001209191-20-002595 · doc4.xml · derivative · entry 3 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
January 07, 2020 Filed Jan 8, 2020 23:01 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	10,000	$42.19	$421,900.00	Disclosure SEC source: 0001209191-20-002595 · doc4.xml · nonDerivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 07, 2020 Filed Jan 8, 2020 23:01 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	10,000	$1.75	$17,500.00	Disclosure SEC source: 0001209191-20-002595 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 10, 2019 Filed Sep 12, 2019 20:21 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	PurchaseCommon Stock	10,000	$11.22	$112,200.00	Disclosure SEC source: 0001209191-19-049309 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document
July 17, 2019 Filed Jul 18, 2019 20:55 UTC	Mirum Pharmaceuticals, Inc. MIRM · Entity 2416	GrantStock Option (right to buy) · Derivative	17,000	$0.00 Strike: $15.00	$0.00	Disclosure SEC source: 0001209191-19-042657 · doc4.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2029-07-16 F1 · derivative.exercise_date: The shares vest in a series of 3 successive equal annual installments measured from July 17, 2019. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. The shares will vest in full upon a change in control, as that term is defined in the Issuer's 2019 Equity Incentive Plan. Read SEC document
June 26, 2019 Filed Jun 28, 2019 21:09 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $25.24	$0.00	Disclosure SEC source: 0001209191-19-039522 · doc4.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-26 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. Read SEC document
June 13, 2019 Filed Jun 17, 2019 17:14 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantStock Option (Right to Buy) · Derivative	6,991	$0.00 Strike: $26.09	$0.00	Disclosure SEC source: 0001209191-19-037435 · doc4.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,991 Underlying: Common Stock · 6,991 shares Expires 2029-06-12 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document
June 13, 2019 Filed Jun 17, 2019 17:14 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	4,194	$0.00	$0.00	Disclosure SEC source: 0001209191-19-037435 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,194 F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs fully vest on March 1, 2020, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date. Read SEC document
June 05, 2019 Filed Jun 6, 2019 20:27 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantStock Option (Right to Buy) · Derivative	8,437	$0.00 Strike: $43.54	$0.00	Disclosure SEC source: 0001209191-19-035072 · doc4.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,437 Underlying: Common Stock · 8,437 shares Expires 2029-06-05 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document
June 05, 2019 Filed Jun 6, 2019 20:27 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantCommon Stock	4,134	$0.00	$0.00	Disclosure SEC source: 0001209191-19-035072 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,761 F1 · shares: Represents restricted stock units that vest on June 3, 2020, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document
May 30, 2019 Filed May 31, 2019 18:26 UTC	DYNAVAX TECHNOLOGIES CORP DVAX · Entity 66930	GrantOption (Right to Buy) · Derivative	15,000	Not disclosed Strike: $4.97	Not disclosed	Disclosure SEC source: 0001209191-19-033719 · doc4.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2026-05-29 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests fully on May 30, 2020, on the one year anniversary of the grant date. Read SEC document
January 09, 2019 Filed Jan 11, 2019 21:32 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $2.16	$0.00	Disclosure SEC source: 0001209191-19-003427 · doc4.xml · derivative · entry 3 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2019-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
January 09, 2019 Filed Jan 11, 2019 21:32 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	10,000	$20.00	$200,041.00	Disclosure SEC source: 0001209191-19-003427 · doc4.xml · nonDerivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 09, 2019 Filed Jan 11, 2019 21:32 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	10,000	$2.16	$21,600.00	Disclosure SEC source: 0001209191-19-003427 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 27, 2018 Filed Jul 30, 2018 21:38 UTC	ARATANA THERAPEUTICS, INC. PETX · Entity 155913	GrantStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $4.36	$0.00	Disclosure SEC source: 0001209191-18-044443 · doc4.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-07-26 F1 · derivative.exercise_date: Vests on the earlier of (i) the first anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's next annual meeting of stockholders following the date of grant, subject to continued service as a member of the Board of Directors of the Issuer through such vesting date. Read SEC document
July 27, 2018 Filed Jul 30, 2018 21:38 UTC	ARATANA THERAPEUTICS, INC. PETX · Entity 155913	GrantCommon Stock	4,500	$0.00	$0.00	Disclosure SEC source: 0001209191-18-044443 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Read SEC document
June 13, 2018 Filed Jun 15, 2018 23:12 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantStock Option (Right to Buy) · Derivative	4,693	$0.00 Strike: $38.35	$0.00	Disclosure SEC source: 0001209191-18-038189 · doc4.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,693 Underlying: Common Stock · 4,693 shares Expires 2028-06-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document
June 13, 2018 Filed Jun 15, 2018 23:12 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantCommon Stock	782	$0.00	$0.00	Disclosure SEC source: 0001209191-18-038189 · doc4.xml · nonDerivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,627 F1 · shares: Represents restricted stock units that vest on June 3, 2019, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document
June 08, 2018 Filed Jun 8, 2018 17:56 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantStock Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $42.81	$0.00	Disclosure SEC source: 0001209191-18-036759 · doc4.xml · derivative · entry 2 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-07 F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.